Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Rating) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.18 and traded as low as $0.17. VistaGen Therapeutics shares last traded at $0.17, with a volume of 2,384,078 shares.
VistaGen Therapeutics Trading Down 3.6 %
The company has a market capitalization of $37.11 million, a price-to-earnings ratio of -0.55 and a beta of 1.09. The company has a fifty day moving average of $0.18 and a 200-day moving average of $0.16.
VistaGen Therapeutics (NASDAQ:VTGN – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. VistaGen Therapeutics had a negative return on equity of 158.24% and a negative net margin of 5,614.37%. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.31 million. As a group, equities research analysts expect that VistaGen Therapeutics, Inc. will post -0.25 EPS for the current year.
Institutional Inflows and Outflows
About VistaGen Therapeutics
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy.
- Get a free copy of the StockNews.com research report on VistaGen Therapeutics (VTGN)
- Hormel Hits 2-Year Low, And The Dip Gets Bought
- Here’s Why Ross Could Soon Be Hitting All Time Highs
- The Bottom Is In For Salesforce.com
- It’s Time For A Fresh Look At The Kroger Co.
- West Fraser’s Earnings Scream Timber, Outlook Says Buy
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.